ReviewMetabolites2023
Antioxidants as Protection against Reactive Oxidative Stress in Inflammatory Bowel Disease.
Review in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Use of Antihistamine Drugs in Colitis: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Trace elements in relation to glycemic control and disease complications in children living with type 1 diabetes mellitus.Journal of clinical biochemistry and nutrition · 2026Article
- 8-Epi-Prostaglandin F2α as a Redox Biomarker in Inflammatory Bowel Disease.Biomedicines · 2026Article
- Interpretable inflammation landscape of circulating immune cells.Nature medicine · 2026Article
- Time-dependent Lactiplantibacillus plantarum (LP) AS21 intervention enhances mesalazine efficacy by modulating gut microbiota and host immunometabolic responses in DSS-induced colitis.Journal of translational medicine · 2026Article
- Preclinical and Limited Clinical Evidence for Spirulina in Ulcerative Colitis: A Systematic Review and Meta-analysis.Advanced pharmaceutical bulletin · 2025Review
- Applications of Antioxidant Nanoparticles in Immune-Mediated Inflammatory Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Gene expression profile in ulcerative colitis patients: FOXO4, ALDOB, SLC26A3, SOD2 genes as potential biomarkers.Genes & genomics · 2025Article
- Oxidative Stress, Gut Bacteria, and Microalgae: A Holistic Approach to Manage Inflammatory Bowel Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Investigating the Health Potential ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Antioxidant Activity of Bovine Colostrum in the Colon of a Mouse Model of TNBS-Induced Colitis.Antioxidants (Basel, Switzerland) · 2025Article
- Transcription Factor Blimp-1: A Central Regulator of Oxidative Stress and Metabolic Reprogramming in Chronic Inflammatory Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Thyroid disorders and inflammatory bowel disease: an association present in adults but also in children and adolescents.Frontiers in endocrinology · 2025Review
- Protective Effects of Peanut Sprouts from a Smart Farming System on the Barrier Function of Human Epithelial Cells.Preventive nutrition and food science · 2024Article
- Protective role of short-chain fatty acids on intestinal oxidative stress induced by TNF-α.Cell stress & chaperones · 2024Article
- Fruit and Vegetable Consumption and Inflammatory Bowel Disease: A Case-Control Study.Life (Basel, Switzerland) · 2024Article
- Mechanism of Action and Therapeutic Implications of Nrf2/HO-1 in Inflammatory Bowel Disease.Antioxidants (Basel, Switzerland) · 2024Review
- 4-Octyl itaconate alleviates dextran sulfate sodium-induced ulcerative colitis in mice via activating the KEAP1-NRF2 pathway.Inflammopharmacology · 2024Article
- Atox1 regulates macrophage polarization in intestinal inflammation via ROS-NLRP3 inflammasome pathway.Journal of translational medicine · 2024Article
- Comparative Assessment of the Anti-Cells · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) belongs to a group of chronic diseases characterised by periods of exacerbation and remission. Despite many studies and observations, its aetiopathogenesis is still not fully understood. The interactions of genetic, immunological, microbiological, and environmental factors can induce disease development and progression, but there is still a lack of information on these mechanisms. One of the components that can increase the risk of occurrence of IBD, as well as disease progression, is oxidative stress. Oxidative stress occurs when there is an imbalance between reactive oxygen species (ROS) and antioxidants. The endogenous and exogenous components that make up the body's antioxidant defence can significantly affect IBD prophylaxis and reduce the risk of exacerbation by neutralising and removing ROS, as well as influencing the inflammatory state.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.